Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders

Richard D. Press, Kenneth A. Bauer, Jody L. Kujovich, John A. Heit

Research output: Contribution to journalArticlepeer-review

115 Scopus citations

Abstract

Objective. - To review the current state of the art regarding the role of the clinical laboratory in diagnostic testing for the factor V Leiden (FVL) thrombophilic mutation (and other protein C resistance disorders), and to generate, through literature reviews and opinions of recognized thought-leaders, expert consensus recommendations on methodology and diagnostic, prognostic, and management issues pertaining to clinical FVL testing. Data Sources, Extraction, and Synthesis. - An initial thorough review of the medical literature and of current best clinical practices by a panel of 4 experts followed by a consensus conference review, editing, and ultimate approval by the majority of a panel of 28 additional coagulation laboratory experts. Conclusions. - Consensus recommendations were generated for topics of direct clinical relevance, including (1) defining those patients (and family members) who should (and should not) be tested for FVL; (2) defining the preferred FVL laboratory testing methods; and (3) defining the therapeutic, prophylactic, and management ramifications of FVL testing in affected individuals and their family members. As FVL is currently the most common recognized familial thrombophilia, it is hoped that these recommendations will assist laboratorians and clinicians caring for patients (and families) with this common mutation.

Original languageEnglish (US)
Pages (from-to)1304-1318
Number of pages15
JournalArchives of Pathology and Laboratory Medicine
Volume126
Issue number11
StatePublished - Nov 2002

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Fingerprint

Dive into the research topics of 'Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders'. Together they form a unique fingerprint.

Cite this